ATE234860T1 - Verwendung von hpv-16 e6 und e7-gen gewonnen peptiden für den diagnostischen zweck - Google Patents

Verwendung von hpv-16 e6 und e7-gen gewonnen peptiden für den diagnostischen zweck

Info

Publication number
ATE234860T1
ATE234860T1 AT92110367T AT92110367T ATE234860T1 AT E234860 T1 ATE234860 T1 AT E234860T1 AT 92110367 T AT92110367 T AT 92110367T AT 92110367 T AT92110367 T AT 92110367T AT E234860 T1 ATE234860 T1 AT E234860T1
Authority
AT
Austria
Prior art keywords
hpv
gene obtained
diagnostic purpose
obtained peptides
peptides
Prior art date
Application number
AT92110367T
Other languages
English (en)
Inventor
Martin Mueller
Lutz Gissmann
Original Assignee
Dade Behring Marburg Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dade Behring Marburg Gmbh filed Critical Dade Behring Marburg Gmbh
Application granted granted Critical
Publication of ATE234860T1 publication Critical patent/ATE234860T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT92110367T 1991-07-13 1992-06-19 Verwendung von hpv-16 e6 und e7-gen gewonnen peptiden für den diagnostischen zweck ATE234860T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP91111720 1991-07-13

Publications (1)

Publication Number Publication Date
ATE234860T1 true ATE234860T1 (de) 2003-04-15

Family

ID=8206929

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92110367T ATE234860T1 (de) 1991-07-13 1992-06-19 Verwendung von hpv-16 e6 und e7-gen gewonnen peptiden für den diagnostischen zweck

Country Status (10)

Country Link
US (1) US5629161A (de)
EP (1) EP0523391B1 (de)
JP (1) JP3366350B2 (de)
AT (1) ATE234860T1 (de)
AU (1) AU667470B2 (de)
CA (1) CA2073616C (de)
DE (1) DE69232963T2 (de)
DK (1) DK0523391T3 (de)
ES (1) ES2193133T3 (de)
PT (1) PT523391E (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69131992T2 (de) * 1990-12-12 2000-06-29 Univ Queensland St Lucia Papillomavirusuntereinheit-impfstoff
US5736318A (en) * 1995-03-17 1998-04-07 President And Fellows Of Harvard College Method and kit for evaluating human papillomavirus transformed cells
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
FR2794370B1 (fr) 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
US6200746B1 (en) 1999-08-25 2001-03-13 Pharmacia & Upjohn Company Methods of identifying anti-viral agents
US6641994B2 (en) 1999-08-25 2003-11-04 Pharmacia & Upjohn Company Methods of identifying anti-viral agents
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
JP2003509035A (ja) * 1999-09-16 2003-03-11 ザイコス インク． ポリエピトープポリペプチドをコードする核酸
FR2794371B1 (fr) * 1999-10-07 2004-06-18 Biovector Therapeutics Fragments proteiquespolyepitopiques, leur obtention et leurs utilisations notamment en vaccination
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
WO2001077142A1 (en) * 2000-04-05 2001-10-18 Impact Diagnostics, Inc. Immunological methodology for discerning human papillomavirus
WO2002009645A2 (en) * 2000-08-01 2002-02-07 The Johns Hopkins University Intercellular transport protein linked to an antigen as a molecular vaccine
JP5087201B2 (ja) * 2000-08-03 2012-12-05 ジョンズ・ホプキンス・ユニバーシティ 抗原に小胞体シャペロンポリペプチドを連結した分子ワクチン
US7312041B2 (en) 2001-02-16 2007-12-25 Arbor Vita Corporation Methods of diagnosing cervical cancer
US6933123B2 (en) * 2001-04-05 2005-08-23 Yao Xiong Hu Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers
FR2824326B1 (fr) * 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
US20060147906A1 (en) * 2002-03-22 2006-07-06 Amynon Biotech Gmbh Anti-hpv-16 e7 antibodies and their use
CA2495449A1 (en) * 2002-09-09 2004-03-18 Arbor Vita Corporation Methods of diagnosing cervical cancer
EP1644048B1 (de) * 2003-05-05 2015-04-29 Johns Hopkins University Anti-krebs-dna-vakzine mit einer für plasmide kodierenden signalsequenz, mutiertes onkoprotein-antigen und hitzeschockprotein
LT5228B (lt) 2003-07-16 2005-06-27 Uždaroji akcinė bendrovė Melofarma Gimdos kaklelio displazijų ir vėžio, susijusių su žmogaus papilomos virusais ankstyvos diagnostikos in vitro būdas
JP5030594B2 (ja) * 2003-12-23 2012-09-19 アルボー ビータ コーポレーション Ｈｐｖの発癌性株に対する抗体およびそれらの使用方法
WO2006073970A2 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
EP1846026A4 (de) * 2005-01-26 2008-07-02 Univ Johns Hopkins Antikrebs-dna-impfstoff mit plasmiden zur kodierung eines mutierten onkoprotein-antigens und von calreticulin
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
WO2008024844A2 (en) * 2006-08-22 2008-02-28 The Johns Hopkins University Anticancer combination therapies
US8278056B2 (en) * 2008-06-13 2012-10-02 Oncohealth Corp. Detection of early stages and late stages HPV infection
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
NZ580242A (en) * 2007-04-05 2012-02-24 Genera Biosystems Ltd Compositions and methods of detection of hpv infection
AU2015213420B2 (en) * 2007-05-31 2017-02-16 Isa Pharmaceuticals B.V. HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
CA3016942C (en) * 2007-05-31 2022-09-20 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
EP2427763A4 (de) 2009-05-07 2013-08-21 Oncohealth Corp Identifikation eines hohen cin2-grades zur erkennung von früh- und spätstadien sowie zum screening und zur diagnose des menschlichen papillomavirus (hpv) und mit diesem assoziierter krebserkrankungen
WO2011084598A1 (en) 2010-01-08 2011-07-14 Oncohealth Corporation High throughput cell-based hpv immunoassays for diagnosis and screening of hpv-associated cancers
CN106632617B (zh) * 2013-02-22 2020-07-03 艾托金生物医药（苏州）有限公司 用于检测抗人***瘤病毒抗体的抗原及相关免疫检测试剂盒
CN109053879B (zh) * 2018-08-22 2020-12-25 深圳市宝安区中心医院 一种治疗***的scFv抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
US5180806A (en) * 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods
FR2641081A1 (de) * 1988-12-23 1990-06-29 Medgenix Group
DE3907721A1 (de) * 1989-03-10 1990-09-20 Behringwerke Ag Immunogene regionen auf dem e7-protein des humanen papillomvierus typ 16
US5045447A (en) * 1989-03-15 1991-09-03 Minson Anthony C Method of producing antibodies to HPV
IE910909A1 (en) * 1990-03-20 1991-09-25 Behringwerke Ag Seroreactive epitopes of human Papillomavirus (HPV) 16¹proteins
SE9001705D0 (sv) * 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay
WO1992005248A1 (en) * 1990-09-26 1992-04-02 Bristol-Myers Squibb Company Human papilloma viral protein expression for use in vaccine compositions

Also Published As

Publication number Publication date
CA2073616A1 (en) 1993-01-14
JP3366350B2 (ja) 2003-01-14
EP0523391A1 (de) 1993-01-20
EP0523391B1 (de) 2003-03-19
US5629161A (en) 1997-05-13
PT523391E (pt) 2003-08-29
DK0523391T3 (da) 2003-06-23
AU1959092A (en) 1993-01-14
DE69232963D1 (de) 2003-04-24
ES2193133T3 (es) 2003-11-01
AU667470B2 (en) 1996-03-28
CA2073616C (en) 2003-11-04
DE69232963T2 (de) 2004-03-04
JPH06169781A (ja) 1994-06-21

Similar Documents

Publication Publication Date Title
ATE234860T1 (de) Verwendung von hpv-16 e6 und e7-gen gewonnen peptiden für den diagnostischen zweck
DE69533544D1 (de) Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
NO20000850D0 (no) Vaksine
NL300273I1 (nl) DNA dat humaan papillomavirus type 18 codeert.
DE69729473D1 (de) Pharmazeutisch-genetische verfahren zur verwendung bei der behandlung von krankheiten des nervensystems
KR950700700A (ko) 척추 및 경막외 공간의 직접가시화용 내시경(Endoscope for direct visualization of the spine and epidural space)
FR10C0016I2 (fr) Procedes et compositions s'appliquant au traitement de la glomerulonephrite
DE69631544D1 (de) Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse
DE69535274D1 (de) Verwendung eines menschlichen interleukin-11 rezeptors
ATE107859T1 (de) Verwendung von antiprogestomimetika zur stimulierung des eisprungs.
ATE172304T1 (de) Alpha b crystallin zur verwendung in diagnose und therapie von autoimmunkrankheiten, besonders multipler skerose
ATE315092T1 (de) Acetylhydrolase des plättchen aktivierenden faktors, und entsprechendes gen
DE69128239D1 (de) DNA SEGMENT DES HERPESVIRUS DER MAREK-KRANKHEIT, WELCHES FÜR DAS GLYKOPROTEIN gE KODIERT
DK0870036T3 (da) Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
DE59410423D1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
TR199802300T2 (xx) �nsan G proteini �3 alt-birimindeki bir gendeki genetik d�n���m�n hastal�klar�n te�hisi i�in kullan�lmas�.
DK383488A (da) Humant papillomavirus type 41, dets dna og deraf kodede proteiner
DE69230550D1 (de) Kernhemmstoff I-92 und seine Verwendung zur Herstellung eines Arzneimittels
ATE74755T1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0523391

Country of ref document: EP

REN Ceased due to non-payment of the annual fee